Papewalis Claudia, Topolar Daniela, Götz Barbara, Schönberger Stefan, Dilloo Dagmar
Department of Pediatric Hematology and Oncology, Center for Pediatrics, University Hospital, Friedrich-Wilhelm University, Bonn, Germany.
Adv Biochem Eng Biotechnol. 2013;130:131-62. doi: 10.1007/10_2012_158.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment option in hematopoietic disorders, immunodeficiencies and leukemia. To date graft-versus-host disease (GvHD) represents a life-threatening complication even if associated with beneficial antileukemic reactivity. GvHD is the clinical manifestation of donor cells reacting against host tissue. Because of their ability to facilitate endogenous repair and to attenuate inflammation, MSC have evolved as a highly attractive cellular therapeutic in allo-HSCT. Here we report on the clinical experience in the use of MSC to enhance engraftment and prevent and treat acute and chronic GvHD. In early clinical trials, MSC have shown considerable benefit in the setting of manifest GvHD. These encouraging results warrant further exploration.
异基因造血干细胞移植（allo-HSCT）是治疗造血系统疾病、免疫缺陷和白血病的一种治愈性治疗选择。迄今为止，即使移植物抗宿主病（GvHD）与有益的抗白血病反应相关，但它仍是一种危及生命的并发症。GvHD是供体细胞对宿主组织产生反应的临床表现。由于间充质干细胞（MSC）具有促进内源性修复和减轻炎症的能力，已发展成为allo-HSCT中极具吸引力的细胞治疗方法。在此，我们报告使用MSC增强植入以及预防和治疗急性和慢性GvHD的临床经验。在早期临床试验中，MSC在明显的GvHD情况下已显示出显著益处。这些令人鼓舞的结果值得进一步探索。
